RFK Jr.’s hand-picked committee approves manufacture of peptides he uses
An FDA committee selected under US health secretary Robert F. Kennedy Jr. has voted to support easing manufacturing restrictions on four peptides for human use, despite limited evidence of their safety or effectiveness. The decision matters because it could expand access to unapproved substances through compounding pharmacies and reflects concerns that the advisory process was shaped to produce a predetermined outcome.
Peptides are short amino-acid chains whose biological effects can be difficult to establish, and many have not been adequately tested in animals or humans. Kennedy had previously signalled his intention to reverse restrictions introduced under the Biden administration, then added committee members with apparent interests in peptide manufacture or sales; those appointees supplied the decisive votes, while all pre-existing members opposed the change. No full clinical, pharmacological or safety evidence was presented, and an FDA official reportedly said the agency had not approved a product never tested in humans.
In short
- FDA panel backs wider peptide manufacture despite limited safety evidence.
- Kennedy appointees provided decisive votes.
- Critics question the committee’s independence and scientific basis.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters contend that RFK Jr. properly exercised his authority by appointing members who share his vision for regulatory reform, noting that involving people with direct expertise and commitment to the field is appropriate governance. They argue that previous FDA restrictions on peptides were unduly restrictive, preventing access to treatments that could benefit patients, and that informed consent can replace some pre-market approval requirements. From this perspective, the appointees voted their genuine convictions about sound policy rather than being corrupted by financial interests, and expanding access represents evidence-based reform.
The case against
Critics argue the committee was deliberately structured to guarantee a predetermined outcome, with members apparently selected partly because of financial interests in peptide sales, whilst every pre-existing independent member opposed the change. This pattern—decisive votes from those with apparent conflicts of interest, unanimous opposition from independent reviewers, and presentation of no clinical evidence—suggests regulatory capture rather than principled policy reform, they contend. Approving untested compounds for human use without proper safety data violates the FDA's core protective function and threatens public health in service of commercial interests.
Explained simply
Robert F. Kennedy Jr. is the current US health secretary and oversees the FDA, the federal agency that regulates medicines and medical manufacturing in America. He has publicly stated his intention to reduce restrictions on certain substances and has been reshaping the advisory committees that guide FDA decisions.
Peptides are short chains of amino acids, the building blocks of proteins, that have become popular in compounding pharmacies and private clinics as wellness treatments. However, most peptides have not been adequately tested in humans or animals, and their long-term safety and effectiveness remain largely unknown.
The concern with Kennedy's approach to FDA oversight relates to how regulatory decisions are made and whether they reflect impartial analysis of evidence. Advisory committees are designed to help the FDA weigh evidence fairly; questions about committee composition and potential conflicts of interest can undermine public trust in the regulatory process itself.